美國(guó)NovaBios埃博拉快速檢測(cè)試劑盒

廣州健侖生物科技有限公司

本司長(zhǎng)期供應(yīng)埃博拉病毒檢測(cè)試劑盒，其主要品牌包括美國(guó)NovaBios、廣州創(chuàng)侖等CDC使用的產(chǎn)品，試劑盒的實(shí)驗(yàn)方法包括膠體金方法、ELISA方法、PCR方法等。

歡迎咨詢

歡迎咨詢2042552662

埃博拉病毒IgM、IgG、ELISA檢測(cè)試劑、埃博拉快速檢測(cè)試劑盒、

埃博拉病毒核酸檢測(cè)試劑盒（熒光探針PCR）

西非工作、旅游埃博拉檢測(cè)試劑盒

美國(guó)CDC使用的埃博拉診斷試劑——美國(guó)的NovaBios

美國(guó)NovaBios 埃博拉快速檢測(cè)試劑盒

【埃博拉簡(jiǎn)介】

埃博拉（Ebola virus）又譯作伊波拉病毒。是一種十分罕見的病毒，1976年在蘇丹南部和剛果（金）（舊稱扎伊爾）的埃博拉河地區(qū)發(fā)現(xiàn)它的存在后，引起醫(yī)學(xué)界的廣泛關(guān)注和重視，“埃博拉”由此而得名。是一個(gè)用來(lái)稱呼一群屬于纖維病毒科埃博拉病毒屬下數(shù)種病毒的通用術(shù)語(yǔ)。是一種能引起人類和靈長(zhǎng)類動(dòng)物產(chǎn)生埃博拉出血熱的烈性傳染病病毒，有很高的死亡率，在50%至90%之間，致死原因主要為中風(fēng)、心肌梗塞、低血容量休克或多發(fā)性器官衰竭。

埃博拉出血熱（EBHF）是由一種絲狀病毒感染導(dǎo)致的急性出血性、動(dòng)物源性傳染病。1976年，埃博拉出血熱在非洲的蘇丹和扎伊爾暴發(fā)，病死率高達(dá)50% ～ 90% 。因該病始發(fā)于扎伊爾北部的埃博拉河流，并在該區(qū)域嚴(yán)重流行，故命名為埃博拉病毒，其形態(tài)學(xué)、致病性等與馬爾堡病毒相似，但免疫原性有所區(qū)別。

【產(chǎn)品介紹】

該產(chǎn)品是世界衛(wèi)生組織（WHO）*個(gè)批準(zhǔn)用于埃博拉病毒檢測(cè)的診斷試劑卡。不需要借助其他實(shí)驗(yàn)儀器設(shè)備，只需要采取幾滴血清、血漿、血液樣品，既可以檢測(cè)，并在15分鐘內(nèi)就可以得知結(jié)果是否感染埃博拉病毒。該產(chǎn)品具有靈敏度高、操作方便、實(shí)驗(yàn)時(shí)間短等特點(diǎn)。

美國(guó)NovaBios

（二）流行病學(xué)特征。
1.傳染源和宿主動(dòng)物
感染埃博拉病毒的人和非人靈長(zhǎng)類動(dòng)物為本病傳染源。
目前認(rèn)為埃博拉病毒的自然宿主為狐蝠科的果蝠，尤其是錘頭果蝠、富氏前肩頭果蝠和小領(lǐng)果蝠，但其在自然界的循環(huán)方式尚不清楚。
2.傳播途徑
接觸傳播是本病zui主要的傳播途徑?？梢酝ㄟ^(guò)接觸病人和被感染動(dòng)物的各種體液、分泌物、排泄物及其污染物感染。
病人感染后血液中可維持很高的病毒含量，醫(yī)護(hù)人員在治療、護(hù)理病人、或處理病人尸體過(guò)程中，如果沒(méi)有嚴(yán)格的防護(hù)措施，容易受到感染。醫(yī)院內(nèi)傳播是導(dǎo)致埃博拉出血熱暴發(fā)流行的重要因素。
據(jù)文獻(xiàn)報(bào)道，埃博拉出血熱患者的埃博拉中可分離到病毒，故存在性傳播的可能性。有動(dòng)物實(shí)驗(yàn)表明，埃博拉病毒可通過(guò)氣溶膠傳播。雖然尚未證實(shí)有通過(guò)性傳播和空氣傳播的病例發(fā)生，但應(yīng)予以警惕，做好防護(hù)。
3.人群易感性和發(fā)病季節(jié)
人類對(duì)埃博拉病毒普遍易感。發(fā)病主要集中在成年人，這和暴露或接觸機(jī)會(huì)多有關(guān)。尚無(wú)資料表明不埃博拉別間存在發(fā)病差異。
目前尚未發(fā)現(xiàn)埃博拉出血熱發(fā)病有明顯的季節(jié)性。
（三）臨床表現(xiàn)。
本病潛伏期為2-21天，一般為5-12天。尚未發(fā)現(xiàn)潛伏期有傳染性。
患者急性起病，高熱、畏寒、極度乏力、頭痛、肌痛、咽痛、結(jié)膜充血及相對(duì)緩脈。隨后可出現(xiàn)埃博拉、嘔吐、腹痛、腹瀉、粘液便或血便、皮疹等表現(xiàn)。
重癥患者可出現(xiàn)神志改變，如嗜睡、譫妄等癥狀。并可出現(xiàn)不同程度的出血表現(xiàn)，包括鼻、口腔、結(jié)膜、胃腸道、埃博拉、皮膚出血或咯血、血尿等，可出現(xiàn)低血壓、休克等?？刹l(fā)心肌炎、肺炎和其它多臟器受損。
（四）病理特點(diǎn)。
主要病理改變是皮膚、粘膜、臟器的出血，多器官可以見到灶性壞死。肝細(xì)胞點(diǎn)、灶樣壞死是本病的典型特點(diǎn)，可見小包含體和凋亡小體。
二、診斷、治療和報(bào)告
埃博拉出血熱臨床早期癥狀無(wú)特殊性，應(yīng)注意與其他病毒性出血熱如拉沙熱、黃熱病、馬爾堡出血熱、克里米亞－剛果出血熱、腎綜合征出血熱等相鑒別。確診主要依靠實(shí)驗(yàn)室檢測(cè)。目前對(duì)埃博拉出血熱尚缺乏*治療方法，主要是對(duì)癥和支持治療，具體參見《埃博拉出血熱診療方案》。
各級(jí)醫(yī)療機(jī)構(gòu)發(fā)現(xiàn)符合病例定義的埃博拉出血熱疑似或確診病例時(shí)，應(yīng)在2小時(shí)之內(nèi)通過(guò)國(guó)家疾病監(jiān)測(cè)信息報(bào)告管理系統(tǒng)進(jìn)行網(wǎng)絡(luò)直報(bào)，報(bào)告疾病類別選擇“其他傳染病”中的“埃博拉出血熱”。按照《國(guó)家突發(fā)公共衛(wèi)生事件相關(guān)信息報(bào)告管理工作規(guī)范（試行）》的要求進(jìn)行突發(fā)公共衛(wèi)生事件或相關(guān)信息的報(bào)告。

美國(guó)NovaBios

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

想了解更多的NovaBios產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

(B) epidemiological characteristics.
1. Infection source and host animal
People infected with Ebola and non-human primates are the source of the disease.
It is not clear that the natural host of the Ebola virus is the fruit bat of the fox bat, especially the hammerhead bat, the rich front shoulder bat and the small fruit bat, but its circulation in nature is unclear.
2. The route of transmission
Exposure to transmission is the most important route of transmission of this disease. Can be through contact with the patient and infected animals, a variety of body fluids, secretions, excreta and contaminants infected.
After the patient's infection can maintain a high viral content in the blood, health care workers in the treatment, care of patients, or handling the body of the patient process, if there is no strict protective measures, vulnerable to infection. Hospital spread is an important factor leading to the outbreak of Ebola haemorrhagic fever.
According to the literature, Ebola hemorrhagic fever patients can be isolated from the Ebola virus, so there is the possibility of sexual transmission. Animal experiments show that Ebola virus can be transmitted through aerosols. Although there have been no confirmed cases of sexual transmission and airborne transmission, but should be vigilant, well protected.
3. Population susceptibility and onset season
Human beings are generally susceptible to Ebola virus. Incidence is mainly concentrated in adults, which is related to exposure or exposure opportunities. There is no data to show that there is no difference between Ebola.
It has not yet been found that Ebola haemorrhagic fever is clearly seasonal.
(C) clinical manifestations.
The incubation period of this disease is 2-21 days, usually 5-12 days. No incubation period has been found to be contagious.
Patients with acute onset, fever, chills, extreme fatigue, headache, myalgia, sore throat, conjunctival hyperemia and relative slow pulse. Followed by Ebola, vomiting, abdominal pain, diarrhea, mucus or bloody stools, rash and other performance.
Severe patients may have signs of change, such as lethargy, delirium and other symptoms. And may occur in varying degrees of bleeding performance, including the nose, mouth, conjunctiva, gastrointestinal tract, Ebola, skin bleeding or hemoptysis, hematuria, etc., there may be low blood pressure, shock and so on. Can be complicated by myocarditis, pneumonia and other multiple organs damaged.
(D) pathological characteristics.
The main pathological changes are skin, mucous membranes, organ bleeding, multiple organs can see focal necrosis. Liver cell point, foci of the disease is the typical characteristics of the disease, showing a small inclusion body and apoptotic bodies.
Second, diagnosis, treatment and reporting
Ebola hemorrhagic fever clinical early symptoms are not specific, should pay attention to other viral hemorrhagic fever such as Rasha fever, yellow fever, Marburg haemorrhagic fever, Crimea - Congo hemorrhagic fever, renal syndrome hemorrhagic fever phase Identification. The diagnosis relies mainly on laboratory testing. At present, there is a lack of special treatment for Ebola hemorrhagic fever, mainly symptomatic and supportive care, see "Ebola Hemorrhagic Fever Treatment Program".
Medical institutions at all levels found that the Ebola Hemorrhagic Suspension or Complicated Cases should be reported within 2 hours of reporting through the National Disease Surveillance Information Reporting Management System. Report the disease category Select the "Other Infectious Diseases" "Ebola haemorrhagic fever". Report on public health emergencies or related information in accordance with the requirements of the National Report on the Management of Public Health Emergencies (Trial Implementation).